Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically…
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in…